Teprotumumab

Teprotumumab

Teprotumumab is a newly approved medication to manage active, moderate to severe thyroid eye disease. Teprotumumab has been approved by the U.S. Food and Drug Administration (FDA) for treating thyroid orbitopathy, under breakthrough therapy designation, as an Orphan Drug. It is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor in the class of biological therapy. This activity describes the indications and evidence supporting each indication, action, and contraindications for teprotumumab as a valuable agent in treating thyroid eye disease. Furthermore, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, monitoring, relevant interactions) pertinent for interprofessional team members in the care of patients with thyroid orbitopathy.

  • Provider:StatPearls, LLC
  • Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/143667
  • Start Date: 2023-09-01 05:00:00
  • End Date: 2023-09-01 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
    Nursing: 1.5 hours
    Pharmacy: 1.5 hours
  • MOC Credit Details: ABS - 1.5 Point; Credit Type(s): Accredited CME (ABS)
    ABPATH - 1.5 Point; Credit Type(s): Lifelong Learning (ABPATH)
    ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
    ABS - 1.5 Point; Credit Type(s): Self-Assessment (ABS)
    ABP - 1.5 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
  • Commercial Support: No
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: Variable
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Directly Provided
  • Registration: Open to all
  • Specialty: All Practice Areas (e.g. ethics), Endocrinology, Diabetes, and Metabolism, General Pediatrics, General Surgery, Internal Medicine, Pediatric Endocrinology
«
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.